IPO News Archive

Sagent Pharmaceuticals prices upsized IPO at $16, high end of the range

4/20/11


Sagent Pharmaceuticals, which markets generic injectable drugs to hospitals, raised $92 million by offering 5.8 million shares (15% more than originally planned) at $16, at high end of the range of $14 to $16. Sagent Pharmaceuticals plans to list on the NASDAQ under the symbol SGNT. Morgan Stanley, BofA Merrill Lynch and Jefferies & Co. acted as lead managers on the deal.
Keywords/Tickers: SGNT
Related Links: Recently Priced IPOs
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest